Akari Therapeutics Files 8-K: Officer/Director Changes & Financials
Ticker: AKTX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1541157
| Field | Detail |
|---|---|
| Company | Akari Therapeutics PLC (AKTX) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $150 million, $18,000, $12,000, $27,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, financials
Related Tickers: AKTX
TL;DR
Akari Therapeutics (AKTX) filed an 8-K detailing leadership changes and financial updates as of Oct 22, 2025.
AI Summary
Akari Therapeutics Plc filed an 8-K on October 23, 2025, reporting events as of October 22, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in Akari Therapeutics' leadership and governance, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can indicate internal shifts that may affect company strategy or stability.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- October 22, 2025 (date) — Date of earliest event reported
- October 23, 2025 (date) — Date of Report
- Celsus Therapeutics Plc. (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any details on new compensatory arrangements?
Yes, the filing covers compensatory arrangements of certain officers.
When was the earliest event reported in this 8-K?
The earliest event reported was on October 22, 2025.
What is the filing date of this 8-K?
The filing date of this 8-K is October 23, 2025.
What were Akari Therapeutics' former company names?
Akari Therapeutics was formerly known as Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
Filing Stats: 941 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-10-23 16:45:53
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $150 million — g the company's headcount, secured over $150 million in financing, built manufacturing infra
- $18,000 — Agreement provides for a monthly fee of $18,000 in cash plus $12,000 in RSUs, vesting a
- $12,000 — r a monthly fee of $18,000 in cash plus $12,000 in RSUs, vesting at the end of each mon
- $27,000 — 2026, the monthly fee will increase to $27,000 in cash plus $13,000 in RSUs, vesting a
- $13,000 — e will increase to $27,000 in cash plus $13,000 in RSUs, vesting at the end of each mon
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 91KB
- 0001493152-25-019112.txt ( ) — 359KB
- aktx-20251022.xsd (EX-101.SCH) — 4KB
- aktx-20251022_def.xml (EX-101.DEF) — 26KB
- aktx-20251022_lab.xml (EX-101.LAB) — 36KB
- aktx-20251022_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: October 23, 2025 By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer